TransMedics Group (NASDAQ:TMDX) Trading Down 9% – Should You Sell?

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price dropped 9% during mid-day trading on Friday . The company traded as low as $80.38 and last traded at $80.38. Approximately 1,600,575 shares were traded during mid-day trading, an increase of 66% from the average daily volume of 966,487 shares. The stock had previously closed at $88.36.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Oppenheimer cut their target price on TransMedics Group from $200.00 to $125.00 and set an “outperform” rating for the company in a research note on Tuesday, October 29th. JPMorgan Chase & Co. reduced their price objective on TransMedics Group from $173.00 to $116.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 29th. Canaccord Genuity Group dropped their target price on shares of TransMedics Group from $169.00 to $109.00 and set a “buy” rating for the company in a report on Tuesday, October 29th. Baird R W raised shares of TransMedics Group to a “strong-buy” rating in a report on Tuesday, September 24th. Finally, Robert W. Baird cut their target price on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, TransMedics Group currently has a consensus rating of “Buy” and an average price target of $144.80.

TransMedics Group Price Performance

The company has a fifty day simple moving average of $125.63 and a 200 day simple moving average of $139.09. The stock has a market capitalization of $2.70 billion, a price-to-earnings ratio of 85.62 and a beta of 2.08. The company has a debt-to-equity ratio of 2.42, a quick ratio of 7.33 and a current ratio of 8.20.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings data on Monday, October 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). The company had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. TransMedics Group had a return on equity of 18.74% and a net margin of 8.14%. TransMedics Group’s revenue was up 63.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.12) earnings per share. Equities research analysts forecast that TransMedics Group, Inc. will post 1.07 EPS for the current fiscal year.

Insider Transactions at TransMedics Group

In other news, insider Tamer I. Khayal sold 2,958 shares of TransMedics Group stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $148.24, for a total value of $438,493.92. Following the completion of the sale, the insider now owns 20,843 shares in the company, valued at $3,089,766.32. The trade was a 12.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction on Tuesday, August 27th. The stock was sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the transaction, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,958 shares of company stock worth $5,230,528 over the last three months. 7.00% of the stock is owned by company insiders.

Institutional Investors Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of TransMedics Group by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after buying an additional 23,979 shares during the period. Driehaus Capital Management LLC boosted its holdings in TransMedics Group by 15.8% in the second quarter. Driehaus Capital Management LLC now owns 1,486,073 shares of the company’s stock worth $223,832,000 after acquiring an additional 202,867 shares in the last quarter. Geode Capital Management LLC grew its stake in TransMedics Group by 1.3% in the third quarter. Geode Capital Management LLC now owns 763,790 shares of the company’s stock valued at $119,938,000 after acquiring an additional 10,106 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of TransMedics Group by 5.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 599,116 shares of the company’s stock valued at $94,061,000 after acquiring an additional 30,092 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. raised its position in shares of TransMedics Group by 24.3% during the third quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock worth $51,654,000 after purchasing an additional 64,360 shares during the period. 99.67% of the stock is owned by institutional investors.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.